Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|October 15, 2019
Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experienceFiras Baidoun, Dong Chen, Mrinal Patnaik, et al.
Transfusion|October 9, 2015
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioningMehrdad Hefazi, Mark Litzow, William Hogan, et al.
Cell Research|October 10, 2018
A dynamic N<sup>6</sup>-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitorsFei Yan, Aref Al-Kali, Zijie Zhang, et al.
Systematic Reviews|September 20, 2018
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndromeJehad Almasri, Hassan B Alkhateeb, Belal Firwana, et al.
Leukemia Research|September 28, 2015
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalitiesMehrdad Hefazi, Mustaqeem Siddiqui, Mrinal Patnaik, et al.
British Journal of Haematology|April 19, 2017
The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalitiesMark Gurney, Mrinal M Patnaik, Curtis A Hanson, et al.
Cancer|September 17, 2010
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemiaAref Al-Kali, Hagop Kantarjian, Jianqin Shan, et al.
Leukemia Research|October 11, 2016
Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experienceRama Nanah, Darci Zblewski, Mrinal S Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2017
Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid LeukemiaNa Shen, Fei Yan, Jiuxia Pang, et al.
Journal of Clinical Medicine|June 2, 2021
Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic HematopathologyMazen Osman, Zeynettin Akkus, Dragan Jevremovic, et al.
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|October 15, 2019
Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experienceFiras Baidoun, Dong Chen, Mrinal Patnaik, et al.
Transfusion|October 9, 2015
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioningMehrdad Hefazi, Mark Litzow, William Hogan, et al.
Cell Research|October 10, 2018
A dynamic N<sup>6</sup>-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitorsFei Yan, Aref Al-Kali, Zijie Zhang, et al.
Systematic Reviews|September 20, 2018
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndromeJehad Almasri, Hassan B Alkhateeb, Belal Firwana, et al.
Leukemia Research|September 28, 2015
Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalitiesMehrdad Hefazi, Mustaqeem Siddiqui, Mrinal Patnaik, et al.
British Journal of Haematology|April 19, 2017
The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalitiesMark Gurney, Mrinal M Patnaik, Curtis A Hanson, et al.
Cancer|September 17, 2010
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemiaAref Al-Kali, Hagop Kantarjian, Jianqin Shan, et al.
Leukemia Research|October 11, 2016
Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experienceRama Nanah, Darci Zblewski, Mrinal S Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2017
Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid LeukemiaNa Shen, Fei Yan, Jiuxia Pang, et al.
Journal of Clinical Medicine|June 2, 2021
Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic HematopathologyMazen Osman, Zeynettin Akkus, Dragan Jevremovic, et al.
Pageof 15